BI 765423 / Enleofen, Boehringer Ingelheim - LARVOL DELTA

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting

Enrollment open

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Sep 2023 ➔ Feb 2024 | Trial primary completion date: Sep 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases (Businesswire) - "Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas....'The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.'"

Preclinical • Trial status • Idiopathic Pulmonary Fibrosis